| [1] |
Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis [J]. Lancet Oncol, 2022, 23(4): 521-530.
|
| [2] |
Chan YT, Zhang C, Wu J, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma [J]. Mol Cancer, 2024, 23(1): 189.
|
| [3] |
贾昌俊, 戴朝六. 中国腹腔镜肝癌根治术式选择与规范化[J/CD]. 中华普外科手术学杂志(电子版), 2022, 16(06): 598-601.
|
| [4] |
陈智全, 刘学军, 木努热丁·艾则孜, 等. 射频消融术和腹腔镜手术治疗原发性小肝癌的前瞻性对照研究[J/CD]. 中华普外科手术学杂志(电子版), 2020, 14(02): 205-207.
|
| [5] |
Liu J, Zhang J, Wang Y, et al. HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis [J]. Medicine(Baltimore), 2022, 101(51): e32390.
|
| [6] |
常小伟, 蔡瑜, 赵志勇, 等. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/CD]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
|
| [7] |
Lin Z, Chen D, Hu X, et al. Clinical efficacy of HAIC (FOLFOX)combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas [J]. Am J Cancer Res, 2023, 13(11): 5455-5465.
|
| [8] |
Liu D, Mu H, Liu C, et al. Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phaseⅡtrial[J]. Neoplasma, 2023, 70(6): 811-818.
|
| [9] |
Zhao X, Sun X, Jing J, et al. Safety study of Folfox-HAIC in relieving bed restriction [J]. J Interv Med, 2021, 4(4): 203-207.
|
| [10] |
Lin Z, Zou X, Hu X, et al. Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma[J]. Sci Rep, 2024, 14(1): 23961.
|
| [11] |
Li SH, Mei J, Cheng Y, et al. Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase Ⅲ, Randomized Study [J]. J Clin Oncol, 2023, 41(10): 1898-1908.
|
| [12] |
Liang Y, Zhong D, Shang J, et al. Efficacy and safety of postoperative adjuvant HAIC with FOLFOX combining PD-1 inhibitors in HCC patients with microvascular invasion: a propensity score matching analysis [J]. BMC Cancer, 2025, 25(1): 418.
|
| [13] |
Li QJ, He MK, Chen HW, et al. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized PhaseⅢTrial [J]. J Clin Oncol, 2022, 40(2): 150-160.
|
| [14] |
杜瑶, 劳茜莹, 唐敏, 等. 不可切除肝细胞癌患者肝动脉灌注化学治疗效果分析[J]. 医药导报, 2023, 42(11): 1723-1728.
|
| [15] |
Ueshima K, Oagasawara S, Ikeda M, et al. Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma [J]. Liver Cancer, 2020, 9(5): 583-595.
|
| [16] |
赵益, 程盛, 王永琛, 等. 肝动脉灌注化疗与经动脉化疗栓塞/栓塞治疗不可切除肝细胞癌疗效与安全性系统评价和Meta分析[J]. 中国普通外科杂志, 2022, 31(07): 860-869.
|
| [17] |
Huang J, Huang W, Zhan M, et al. Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma [J]. J Hepatocell Carcinoma, 2021, 8: 1445-1458.
|
| [18] |
中国抗癌协会肝癌专业委员会. 肝动脉灌注化疗治疗肝细胞癌中国专家共识（2021版）[J]. 中华消化外科杂志, 2021, 20(07): 754-759.
|
| [19] |
Lu D, Li H, Sun P, et al. Systemic therapy plus HAIC versus systemic therapy for hepatocellular carcinoma: a systematic review and meta-analysis [J]. Int J Surg, 2025, 111(5): 3494-3507.
|
| [20] |
Zheng K, Zhu X, Fu S, et al. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial [J]. Radiology, 2022, 303(2): 455-464.
|
| [21] |
Lyu N, Wang X, Li JB, et al. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase Ⅲ Trial (FOHAIC-1) [J]. J Clin Oncol, 2022, 40(5): 468-480.
|
| [22] |
Han S, Bao X, Zou Y, et al. d-lactate modulates M2 tumor-associated macrophages and remodels the immunosuppressive tumor microenvironment for hepatocellular carcinoma[J]. Sci Adv, 2023, 9(29): eadg2697.
|
| [23] |
陶杰, 史政荣. 联合卡瑞利珠单抗和仑伐替尼的肝动脉灌注化疗与肝动脉化疗栓塞对不可切除肝细胞癌的疗效对比[J]. 重庆医学, 2023, 52(18): 2758-2763.
|
| [24] |
孙铭强, 吴琴, 李妍欣, 等. 信迪利单抗联合HAIC治疗中晚期肝细胞癌的疗效及对肿瘤相关凋亡分子、免疫分子的影响[J]. 四川医学, 2024, 45(12): 1386-1391.
|
| [25] |
陈路皓, 杨奕, 张精文, 等. 经肝动脉灌注化疗或化疗栓塞术联合酪氨酸激酶抑制剂及卡瑞利珠单抗治疗不可切除肝细胞癌的对比研究[J]. 介入放射学杂志, 2024, 33(05): 543-548.
|
| [26] |
刘禹辰, 朱建交, 陶计林, 等. 肝动脉灌注化疗联合仑伐替尼、卡瑞利珠单抗治疗不可切除肝癌的临床观察[J]. 中国药物应用与监测, 2023, 20(04): 221-225.
|
| [27] |
李有赞, 陈凯, 赵冀, 等. 肝动脉灌注化疗联合免疫及靶向治疗不可切除肝癌的临床研究[J]. 实用医院临床杂志, 2022, 19(03): 42-46.
|
| [28] |
Zhou SA, Zhou QM, Wu L, et al. Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis[J]. World J Gastrointest Oncol, 2024, 16(8): 3672-3686.
|
| [29] |
Tan HY, Liu SQ, Zheng JL, et al. Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study [J]. Abdom Radiol (NY), 2025, 50(3): 1320-1329.
|
| [30] |
Chiang CL, Liang HL, Chang KC, et al. Advanced hepatocellular carcinoma with major portal vein invasion: Therapeutic outcomes of hepatic arterial infusion chemotherapy vs concurrent radiotherapy [J]. J Chin Med Assoc, 2024, 87(2): 171-178.
|
| [31] |
Hu Z, Liu Y, Jiang J, et al. Clinical study of HAIC via left distal branchial radial artery route in the treatment of liver tumors[J]. Minerva Gastroenterol (Torino), 2024, 70(1): 128-131.
|